Literature DB >> 1466190

Hypoparathyroidism in beta-thalassemia major. Clinical and laboratory observations in 24 patients.

V De Sanctis1, C Vullo, B Bagni, L Chiccoli.   

Abstract

In the last 18 years, we have observed 24 cases of hypoparathyroidism (HPT) in beta-thalassemia major. At present, 4.5% of patients followed regularly in our department have this complication. HPT is thought to be mainly the consequence of iron deposition in the parathyroid glands. The age of our patients when HPT was diagnosed ranged from 11 to 24 years (mean 16.5 years). Their serum ferritin levels ranged from 810 to 15,200 ng/ml (mean 3,772 ng/ml). The severity of HPT varied widely. In only 3 patients was hypocalcemia severe with signs of tetany, seizures or cardiac failure. The onset of HPT was preceded or followed in most patients by other endocrine and/or cardiac complications. We found no clear relationship between HPT and serum ferritin levels in our patients, suggesting either an individual sensitivity to iron toxicity or early damage of the parathyroid gland before chelation had reduced the iron overload. However, the diagnosis of no new cases of HPT in the last 3 years coinciding with the much improved regime of chelation therapy suggests that chelation may have helped to prevent the development of HPT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1466190     DOI: 10.1159/000204662

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  17 in total

1.  Thyroid function in major thalassemia patients: Is it related to height and chelation therapy?

Authors:  Peiman Eshragi; Ahmad Tamaddoni; Khadijeh Zarifi; Amir Mohammadhasani; Majid Aminzadeh
Journal:  Caspian J Intern Med       Date:  2011

2.  Hypocalcemic heart failure in thalassemic patients.

Authors:  M Tsironi; K Korovesis; D Farmakis; S Deftereos; A Aessopos
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

3.  Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia.

Authors:  Nicholas G Angelopoulos; Anastasia Goula; Grigorios Rombopoulos; Victoria Kaltzidou; Eugenia Katounda; Dimitrios Kaltsas; George Tolis
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

4.  Parathyroid and calcium status in patients with thalassemia.

Authors:  Meenu Goyal; Pankaj Abrol; Harbans Lal
Journal:  Indian J Clin Biochem       Date:  2010-09-14

5.  Renal function in children with beta-thalassemia major and thalassemia intermedia.

Authors:  Vladislav Smolkin; Raphael Halevy; Carina Levin; Miguel Mines; Waheeb Sakran; Katzap Ilia; Ariel Koren
Journal:  Pediatr Nephrol       Date:  2008-06-25       Impact factor: 3.714

6.  Impact of genotype on endocrinal complications in β-thalassemia patients.

Authors:  Ahmed Al-Akhras; Mohamed Badr; Usama El-Safy; Elisabeth Kohne; Tamer Hassan; Hadeel Abdelrahman; Mohamed Mourad; Joaquin Brintrup; Marwa Zakaria
Journal:  Biomed Rep       Date:  2016-04-04

7.  Prevalence of Hypoparathyroidism (HPT) in Beta Thalassemia Major.

Authors:  Khalida Parveen Basha N; Beena Shetty; U V Shenoy
Journal:  J Clin Diagn Res       Date:  2014-02-03

8.  Diffuse hepatic calcifications in a transfusion-dependent patient with Beta-thalassemia: a case report.

Authors:  Forough Saki; Mohammad Reza Bordbar; Mohammad Hadi Imanieh; Mehran Karimi
Journal:  Iran J Med Sci       Date:  2013-09

9.  Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines.

Authors:  Vincenzo De Sanctis; Ashraf T Soliman; Heba Elsedfy; Nicos Skordis; Christos Kattamis; Michael Angastiniotis; Mehran Karimi; Mohd Abdel Daem Mohd Yassin; Ahmed El Awwa; Iva Stoeva; Giuseppe Raiola; Maria Concetta Galati; Elsaid M Bedair; Bernadette Fiscina; Mohamed El Kholy
Journal:  Indian J Endocrinol Metab       Date:  2013-01

Review 10.  Vitamin d status in thalassemia major: an update.

Authors:  Ashraf Soliman; Vincenzo De Sanctis; Mohamed Yassin
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-09-02       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.